医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集
▼×

医学

CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China

CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: CANbridge Life Sciences Receives Approval Trial in Esophageal Squamous Cell Cancer

2018年08月14日

0

AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China

AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Application for CAN017 AVEO Announces Acceptance of CANbridge Trial in Esophageal Squamous Cell Cancer

2018年08月14日

0

STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement

STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement

ヘルスケアヘルス一般医療機器外科眼科医療　 TimeLine: Cooperation Agreement STAAR Surgical and Shinjuku LASIK Clinic

2018年08月14日

0

AVITA Medical Announces Expanded Compassionate Use of RECELL® Device in Life-Threatening Burns

AVITA Medical Announces Expanded Compassionate Use of RECELL® Device in Life-Threatening Burns

バイオテクノロジーヘルスケアヘルス一般医療機器外科　 TimeLine: AVITA Medical Announces Expanded Compassionate Use in Life-Threatening Burns

2018年08月09日

0

Glen Richards-Backed Healthia Limited to List on the ASX$26.8m Initial Public Offer Opens

Glen Richards-Backed Healthia Limited to List on the ASX$26.8m Initial Public Offer Opens

ヘルスケア理学療法　 TimeLine: Glen Richards-Backed Healthia Limited to List on Initial Public Offer Opens

2018年08月09日

0

Genome Editing Biotech Company EdiGene Raises $15 Million in Series pre-B Financing

Genome Editing Biotech Company EdiGene Raises $15 Million in Series pre-B Financing

バイオテクノロジーヘルスケア製薬遺伝学　 TimeLine: Genome Editing Biotech Company EdiGene Raises pre-B Financing

2018年08月08日

0

Ambys Medicines and Takeda Announce Partnership to Pioneer First-in-Class Therapies for the Treatment of Serious Liver Diseases

Ambys Medicines and Takeda Announce Partnership to Pioneer First-in-Class Therapies for the Treatment of Serious Liver Diseases

バイオテクノロジーヘルスケアヘルス一般製薬遺伝学　 TimeLine: Ambys Medicines and Takeda Announce Partnership First-in-Class Therapies for the Treatment

2018年08月08日

0

Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China

Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: $2 000 000 Upfront Payment as Part Can-Fite Receives from CMS Medical Venture Marketing Agreement for Piclidenoson

2018年08月07日

0

PaceMate™ Partners with SeaMercy on Pacific Islands Healthcare Mission

心臓学　 TimeLine: Partners with SeaMercy on Pacific Islands

2018年08月07日

0

Harbour BioMed and Glenmark Pharmaceuticals Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers

Harbour BioMed and Glenmark Pharmaceuticals Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers Greater China to Develop GBR 1302 Harbour BioMed and Glenmark Pharmaceuticals Sign

2018年08月07日

0